Moderna, Merck Find 42% Lower Melanoma Recurrence-or-Death Risk

2 outlets reporting

Your call?🐂 Bullish🐻 Bearish

42%

lower recurrence risk

Estimated two-year recurrence-free survival was 82.2% with the combination and 70.0% with Keytruda alone; overall-survival data remain immature.